Rufinamide

Introduction Overview

Generic Name

rufinamide

Brand Name

Banzel

Dosage Form

Oral tablet, oral suspension (liquid)

Drug Class

Dibenzazepine anticonvulsants

Pharmacokinetics

Absorption

Rufinamide is well absorbed after oral administration, with bioavailability influenced by food intake. Taking Banzel with food enhances its absorption, leading to increased plasma concentrations. Peak plasma levels are typically reached within 6 hours post-dose. The drug’s absorption is nearly complete, but coadministration with food delays the time to peak concentration without significantly impacting the extent of absorption. Factors such as gastrointestinal motility and concomitant medications may alter the rate but not the overall extent of absorption.

Distribution

Rufinamide exhibits moderate plasma protein binding, approximately 34%, which is relatively low compared to other anticonvulsants, thereby contributing to its distribution profile. It distributes widely into body tissues, but the extent of penetration into cerebrospinal fluid (CSF) is limited, consistent with its central nervous system activity. The volume of distribution is estimated to be moderate, facilitating effective concentrations in the brain to exert anticonvulsant effects. Distribution may be altered in patients with altered plasma protein levels or comorbid conditions affecting blood-brain barrier permeability.

Metabolism

Rufinamide undergoes predominant hepatic metabolism through hydrolytic cleavage of the carboxamide group by amidase enzymes rather than cytochrome P450 oxidative pathways. This unique metabolic pathway reduces the likelihood of drug-drug interactions mediated by cytochrome P450 enzymes. Metabolism is not significantly influenced by common inducers or inhibitors of hepatic enzymes. There is no evidence of active metabolites contributing to clinically relevant anticonvulsant activity. The drug’s metabolic profile supports predictable pharmacokinetics and makes it favorable for use with other antiepileptics.

Elimination

The elimination of rufinamide primarily occurs via renal excretion of metabolites and unchanged drug. Approximately 85% of the dose is recovered in urine, mainly as inactive metabolites and less than 5% as unchanged drug. The elimination half-life ranges from 6 to 10 hours in adults, but it can be shorter in pediatric populations. Clearance may be reduced in patients with severe hepatic impairment, necessitating caution. There is minimal biliary or fecal excretion. Dose adjustments may be needed based on renal or hepatic function to avoid accumulation and toxicity.

Dosage Forms

Adults

For adults with Lennox-Gastaut syndrome, initial dosing starts at 400 to 800 mg per day divided into two doses, with gradual titration by 400 to 800 mg every other day to reach a maximum daily dose of 3200 mg. The maintenance dose is generally 1600 mg twice daily. Dose adjustments are necessary when used concomitantly with valproate due to pharmacokinetic interactions that increase rufinamide levels.

Adolescents

In pediatric patients aged 1 year and older, the initial dose is 10 mg/kg/day in two divided doses, titrated every other day by 10 mg/kg to a target dose of 45 mg/kg/day, not exceeding 3200 mg/day. This weight-based dosing ensures effective seizure control while minimizing adverse effects. Like adults, patients on valproate require lower initial doses and slower titration.

Special Populations

Banzel is contraindicated in patients with severe liver disease and short QT syndrome due to risk of adverse effects. Patients with renal impairment may require close monitoring though specific dose adjustments have not been fully established. It is not recommended for children under 1 year of age. Use during pregnancy requires careful evaluation; rufinamide may reduce hormonal contraceptive efficacy, necessitating alternative contraceptive methods. The safety of breastfeeding during rufinamide treatment is uncertain, and breast feeding mothers should consult healthcare providers before use. Geriatric dosing adjustments are not specifically defined but cautious use is advised given potential comorbidities and altered pharmacokinetics.

Mechanism Of Action

Rufinamide’s precise mechanism of action remains incompletely understood; however, it is believed to exert its anticonvulsant effects primarily through modulation of voltage-gated sodium channels in neuronal membranes. Specifically, rufinamide prolongs the inactive state of these sodium channels, which stabilizes hyperexcitable neuronal membranes and prevents repetitive firing of action potentials that characterize seizures. By inhibiting sustained high-frequency firing, it reduces neuronal excitability and seizure propagation.

Pharmacological Actions

Inhibition of voltage-gated sodium channels to reduce neuronal hyperexcitability
Modulation of neuronal firing rates and impulse conduction
Adjunctive anticonvulsant activity against multiple seizure types including tonic-atonic and atypical absence seizures
Potential stabilization of neuronal membranes without significant sedative effects
Minimal effect on cytochrome P450 enzyme system, reducing drug interaction potential
Reduction of seizure frequency in Lennox-Gastaut syndrome
Improvement in seizure control via combinational therapy with other antiepileptic drugs
Demonstrated efficacy in refractory epilepsy as adjunctive therapy

Therapeutic Clinical Uses

Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in adults and children aged 1 year and older
Management of complex seizures resistant to other therapies
Used as part of combination antiepileptic therapy to reduce seizure burden in severe epilepsy syndromes
Potential off-label use in other refractory seizure disorders (clinical discretion required)
Supportive therapy to improve patient quality of life by reducing seizure frequency

Side Or Adverse Effects

Common side effects include headache, dizziness, and somnolence
Nausea and fatigue frequently reported during initiation or titration
Loss of coordination (ataxia) and difficulty walking can occur, warranting caution
Mood disturbances including anxiety, depression, irritability, and hyperactivity have been observed
Rare severe skin reactions such as Stevens-Johnson syndrome reported as post-marketing events
Potential for suicidal ideation and behavior necessitates monitoring
Gastrointestinal symptoms like abdominal pain and vomiting
Hypersensitivity reactions including rash, swelling, and allergic reactions
Exacerbation or worsening of seizure frequency possible if medication stopped abruptly or dose altered inappropriately
Fatigue and malaise affecting daily activities

Precautions

Avoid abrupt discontinuation to prevent increased seizure frequency
Use cautiously in patients with underlying liver, kidney, or cardiac conditions
Monitor patients for behavioral and mood changes including suicidal ideation
Rufinamide may reduce the efficacy of hormonal contraceptives; barrier methods recommended for women of childbearing potential
Regular monitoring of liver and kidney function advised during prolonged therapy
Ensure adequate patient and caregiver education on seizure control and medication adherence
Use with caution in elderly patients or those with multiple comorbidities
During pregnancy, careful risk-benefit assessment is essential due to potential fetal risk
Avoid driving or operating machinery until effects on cognition and coordination are known
Monitor valproate coadministration closely due to pharmacokinetic interactions

Warnings

Contraindicated in severe hepatic impairment due to altered metabolism and increased adverse reaction risk
Not for use in patients with short QT syndrome, a cardiac genetic disorder linked to arrhythmias
Potential for mood and behavioral changes including suicidal thoughts necessitates clinical vigilance
Risk of serious hypersensitivity including skin rash and multiorgan involvement
Sudden discontinuation can precipitate increased or more severe seizures
Potential drug interactions with other CNS depressants augmenting sedation
Recommended to store oral suspension properly and discard after 90 days of opening
Inform healthcare providers prior to initiating or stopping therapy to ensure safe titration and monitoring

Contraindications

Hypersensitivity or allergy to rufinamide or components of Banzel formulation
Severe liver disease with compromised metabolic capacity
Short QT syndrome genetically determined cardiac arrhythmia disorder
Children under 1 year of age, due to insufficient safety data
Use is contraindicated in patients with known severe adverse reaction history to rufinamide

Drug Interactions

Valproic acid increases plasma rufinamide concentrations, necessitating dosage adjustments
Additive CNS depression when combined with opioids, benzodiazepines, muscle relaxants, or other sedatives
Rufinamide may reduce efficacy of hormonal contraceptives via hepatic enzyme induction, potentially leading to contraceptive failure
Concurrent use with drugs affecting cardiac conduction should be closely monitored
No significant cytochrome P450 interactions reported, reducing potential for widespread drug metabolism interactions
Interaction potential with other antiepileptic drugs requires careful therapeutic monitoring
Co-administration with alcohol may exacerbate drowsiness and impair cognitive function
Potential for altered renal clearance when combined with nephrotoxic agents, warranting renal function monitoring

Preparations Of The Drug

Oral tablet, scored, available for administration whole, halved, or crushed
Oral suspension (liquid) for patients unable to swallow tablets, packaged with dosing syringe and bottle adapter for accurate measurements
Available in various strengths for titration and maintenance doses
Packaged with detailed instructions for use to ensure accurate dosing and storage
Prescribed in divided doses, typically twice daily, with food to improve absorption
Commercially available as branded Banzel formulation
Supplied with medication guides highlighting risks, side effects, and counseling points